Yakult Seeks Additional Indication For Colon Cancer Drug Elplat
This article was originally published in PharmAsia News
Executive Summary
Yakult Honsha applied for an additional indication with Japan's Ministry of Health, Labor and Welfare for Elplat (exaliplatin), a drug approved to treat progressive, recurring colon cancers and colon cancers that cannot be eliminated by surgery. The additional indication is to use the drug as a supplement to chemotherapy after colon cancer surgery. With the July 2009 expiration of patent protection for its major cancer drugCampto (irinotecan), Yakult aims to increase Elplat's target patients and expand the market to increase sales. (Click here for more - Japanese language) "Yakult Applies For Additional Indications For Cancer Drug" - Nikkei Sangyo News (9/2/08)